Skip to content

Saturday, 21 November 2026 · New Delhi

Science & Tech

Healing with Science: Health Technologies

The silent pandemic of AMR, India's TB elimination push, the vaccines that made it the pharmacy of the world, stem cells, digital health and AYUSH: how science reaches a billion patients.

By Harsh28 September 2026Updated 21 November 202645 min readintermediate
Healing with Science: Health Technologies | UPSC

Health technology is the application of scientific knowledge and tools to prevent, diagnose and treat disease, from a vaccine vial to a telemedicine app. For UPSC, this is one of the highest-yield areas of science and technology: it connects the silent pandemic of drug resistance, India's push to eliminate tuberculosis, the vaccine platforms that made the country the pharmacy of the world, and the digital and traditional systems reshaping how care reaches a billion people.

The silent pandemic: antimicrobial resistance

Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites evolve so that medicines which once killed them no longer work. It is called the silent pandemic because it kills without headlines: routine operations, childbirth and chemotherapy all become dangerous when antibiotics fail. India is one of its global epicentres, which is why nearly every recent UPSC paper has probed some angle of it.

The drivers are well mapped. In clinics, broad-spectrum antibiotics are overprescribed for viral fevers, and weak enforcement of Schedule H1, the rule restricting over-the-counter sale of potent antibiotics, feeds a pill-popping culture; about nearly 55 percent of antibiotics consumed in India in 2019 belonged to the Watch category, drugs meant to be used sparingly. In farms, antibiotics such as colistin are routinely used as growth promoters in poultry and aquaculture, and India ranks as the world's fourth-largest consumer of animal antibiotics, with use projected to rise sharply by 2030. Drug factories add pharmaceutical pollution: untreated effluents have left stretches of Hyderabad's Musi river with antibiotic levels far above safe limits. Irrational fixed-dose combinations, cocktail drugs with no scientific rationale, led the government to ban 156 such combinations in 2024, while poor sanitation lets resistant bacteria travel from hospitals into rivers, soil and food.

The costs are counted in lives and rupees. More than 58,000 newborns die each year in India from drug-resistant infections, a 2013 estimate that the study's authors themselves called an underestimate; drug-resistant tuberculosis threatens the urban poor, and the World Bank has estimated that AMR could shave 3.8 percent off global GDP by 2050 through prolonged illness, expensive last-line drugs and lost productivity. India's response is organised around One Health, the recognition that human, animal and environmental health are one connected system. The National Action Plan on AMR 2.0 (2025-29) is the current national framework, building on the 2017 Delhi Declaration that brought ministries together. Visible instruments include the Red Line campaign, which marks antibiotic strips with a red stripe to warn against self-medication, the ban on colistin in animal feed, a May 2025 prohibition of 34 antimicrobial products in animal use, the ICMR AMR Surveillance Network, the India AMR Innovation Hub, anchored by C-CAMP Bengaluru, serves as the innovation arm of NAP-AMR 2.0, while Kerala and Gujarat have become the first states to ban over-the-counter antibiotic sales. The way forward that experts prescribe is diagnostic-led: rapid test kits at primary health centres so doctors stop prescribing blindly, cleaner pharma supply chains, farm-to-fork traceability for poultry, and behaviour-change campaigns that make finishing the full antibiotic course a social norm.

Training the immune system: vaccines

1985Universal Immunisation ProgrammeFree vaccines against 12 diseases begins2014Mission IndradhanushTargets unvaccinated and partially vaccinated childrenJan 2021CDSCO emergency nodCOVAXIN and Covishield authorised for COVID-19Aug 2021ZyCoV-DWorld's first plasmid DNA vaccine, needle-freeNov 2021COVAXIN WHO listingEmergency use listing; exported under Vaccine MaitriJan 2023CERVAVACIndia's first indigenous HPV vaccine against cervical cancerJun 2023GEMCOVAC-OMFirst indigenous mRNA vaccine, stable at 2 to 8 degrees
From the Universal Immunisation Programme in 1985 to indigenous mRNA vaccines in 2023.

A vaccine is a biological preparation that trains the immune system to recognise and fight a specific pathogen, so the body defeats the real infection before it takes hold. Vaccines work by presenting the immune system with a harmless stand-in, a killed or weakened microbe, a fragment of it, or genetic instructions to make a pathogen protein, and letting the body build antibodies and memory cells in advance. This basic principle, expose safely now to protect later, underlies every immunisation drive on earth.

Four platforms dominate. Inactivated vaccines use killed pathogens, as in the polio shot. Live-attenuated vaccines use weakened pathogens that mimic natural infection, as in measles vaccine. Viral vector vaccines smuggle pathogen genes into cells using a harmless carrier virus. And nucleic acid vaccines deliver DNA or mRNA instructions so the body's own cells manufacture the target protein, the technology behind COVID-19 mRNA shots. India's manufacturers mastered all four during the pandemic. COVAXIN, an inactivated vaccine, and ZyCoV-D, the world's first plasmid DNA vaccine for COVID-19, granted emergency authorisation in August 2021 and delivered needle-free to adolescents, showed the range of indigenous platforms. GEMCOVAC-OM, an mRNA-based Omicron booster, extended it further.

Platform

What it delivers

Example

Inactivated

Killed pathogen

Covaxin, injectable polio vaccine

Live-attenuated

Weakened pathogen that mimics natural infection

Measles vaccine

Viral vector

A harmless carrier virus delivers pathogen genes into cells

Covishield

Nucleic acid (DNA/mRNA)

Genetic instructions so the body's own cells make the target protein

ZyCoV-D (DNA), GEMCOVAC-OM (mRNA)

Messenger RNA vaccines work by introducing a piece of mRNA that corresponds to a viral protein: the body's own cells read the instructions, manufacture the protein, and the immune system learns to recognise and attack it. Where most platforms inject the virus or a part of it, mRNA teaches the cell to make the antigen, which is why the same basic technology can be redirected to a new virus simply by rewriting the mRNA sequence. On safety, the key fact UPSC has tested is that the mRNA does not enter the cell nucleus and does not alter the recipient's DNA; it degrades naturally within the body. The trade-offs are speed and flexibility against complex manufacturing and cold-chain demands.

India's proof of the platform is GEMCOVAC-OM, developed by Pune-based Gennova Biopharmaceuticals with DBT and BIRAC funding under Mission COVID Suraksha. Granted emergency use authorisation by the Drugs Controller General of India in June 2023, it is India's first indigenous mRNA vaccine against the Omicron variant. Unlike imported mRNA shots that need deep-freeze chains, it is lyophilised, stable at 2 to 8 degrees Celsius in ordinary refrigeration, and delivered needle-free into the skin with the PharmaJet Tropis device.

How an mRNA vaccine works1. mRNA deliveredsynthetic mRNA entersa body cell2. Protein builtribosomes read the mRNAand make spike protein3. Immune responsethe body raises antibodiesand memory cellsThe mRNA never alters DNAit is read in the cytoplasm and then breaks down
An mRNA vaccine delivers a synthetic messenger RNA strand; the cell's ribosomes use it to build a harmless piece of viral protein such as the spike, and the immune system learns to recognise it and stores antibodies and memory cells.

The pandemic built on a deeper base. India supplies about 60 percent of the world's immunisation doses and is called the pharmacy of the world for good reason: it is the third-largest producer of pharmaceuticals by volume and a top supplier of generic drugs and vaccines globally. In January 2023 the Serum Institute of India launched CERVAVAC, India's first indigenously developed quadrivalent HPV vaccine against cervical cancer, developed with the DBT, BIRAC and the Gates Foundation, and launched on National Girl Child Day. The domestic backbone is the Universal Immunisation Programme (UIP), running since 1985 and now providing free vaccines against 12 diseases, tracked digitally through Co-WIN. The persistent challenges are vaccine hesitancy fed by misinformation, rural-urban gaps in coverage, cold-chain logistics, and staying ready for the next novel pathogen.

Ending an old killer: the TB elimination push

21%Incidence fallBetween 2015 and 2024187Cases per lakhDown from 237 in 201592%Treatment coverageUp from about 53 percentRs 1,000Monthly supportNikshay Poshan Yojana, doubled 20247 lakh+Cases detectedIn the 100-day 2024-25 campaign6 monthsBPaLM regimenAll-oral drug-resistant TB therapy
Falling incidence, rising coverage: the numbers behind the TB Mukt Bharat drive.

Tuberculosis (TB) is an infectious disease caused by the bacterium *Mycobacterium tuberculosis*, which most often attacks the lungs and spreads through the air when an infected person coughs or sneezes. It is curable and preventable, yet India carries 26 percent of the world's TB cases, about 27 lakh new cases a year, the highest national burden on the planet. That is why the National TB Elimination Programme (NTEP) is one of the most examined health missions in the syllabus.

The complication is resistance. Drug-sensitive TB responds to first-line drugs such as isoniazid and rifampicin. Multidrug-resistant TB (MDR-TB) resists both, needing longer, costlier second-line treatment, and India holds about 27 percent of the world's MDR cases. Extensively drug-resistant TB (XDR-TB) resists second-line drugs as well. Undernutrition is the single largest risk factor for TB in India, contributing to roughly a third of the burden, and stigma still keeps patients from seeking care early.

The programme's arsenal has expanded sharply. Nikshay Poshan Yojana pays Rs 1,000 a month directly to patients for nutrition during treatment, doubled from Rs 500 in October 2024. The 100-day accelerated TB campaign of 2024-25 detected over 7 lakh cases through intensive screening. Newer drugs bedaquiline and delamanid have made drug-resistant TB treatment safer, and India has moved to an all-oral BPaLM regimen that shortens therapy to six months. Two indigenous TB vaccine candidates, VPM1002 and MIP (Mycobacterium Indicus Pranii, being developed as Immuvac) both proved safe, and VPM1002 showed 50.4 percent efficacy against extrapulmonary TB in the 12,717-person PreVenTB Phase III trial, published in The BMJ in April 2026, though neither worked against all forms of TB. Digitally, the Ni-kshay 2.0 portal unifies patient management and benefit transfers, TB Mukt Panchayat awards TB-free status to gram panchayats for local accountability, and Ni-kshay Mitra, under the Pradhan Mantri TB Mukt Bharat Abhiyaan, lets citizens and organisations adopt patients for nutritional support. The results are real: TB incidence fell 21 percent between 2015 and 2024, from 237 to 187 per lakh population, well ahead of the global decline, and treatment coverage rose from about 53 percent to 92 percent in 2024.

The campaign's second wind came in 2026. Cumulative screenings have crossed 28.1 crore, more than 20 lakh people have received preventive treatment, 5.7 lakh new community supporters have signed up, and 46,118 gram panchayats have earned TB-free certification. Screening itself has been transformed by handheld X-ray units — a 34-fold surge, with more than 500 AI-enabled handheld units in the field and 1,500 more being delivered — and by a new app carrying an AI chatbot, Khushi, that tracks progress, explains symptoms and points users to nearby diagnostic centres. The community push now has a youth face: the JOSH campaign, launched on 13 October 2026 across eleven states and fifty-five districts, fields teams of MY Bharat youth volunteers, National Cadet Corps cadets and a designated Class-I officer to spread awareness, find cases early and fight stigma. Anyone with symptoms can call the toll-free Ni-kshay Sampark helpline, 1800-11-6666, or use the TB Aarogya Sathi app to find the nearest centre and get guidance on side effects and nutrition. The nutrition support itself is now Rs 1,000 a month per patient — doubled from Rs 500 in October 2024 — with Rs 4,454.68 crore transferred to 1.38 crore beneficiaries since the scheme began in April 2018. The World Health Organization's 2025 global tuberculosis report records the direction of travel: deaths down 28 per cent between 2015 and 2024, with treatment coverage at 92 per cent against a 78 per cent global figure.

Regrowing the body: stem cell therapy

Stem cell therapy is the use of stem cells, the body's master cells that can both renew themselves and differentiate into specialised cell types, to repair, replace or regenerate damaged tissues and organs. Because a single stem cell can become bone, nerve, muscle or blood, the therapy promises what drugs cannot: rebuilding rather than merely treating.

Four types matter for the exam. Embryonic stem cells, taken from early-stage embryos, are pluripotent, able to become any cell type, but their use raises ethical objections about embryo destruction. Adult stem cells, found in bone marrow and fat, are multipotent, limited to a narrower family of cell types. Mesenchymal stem cells, from bone marrow, fat or umbilical cord tissue, are used in orthopaedic, cardiac and autoimmune treatments. And induced pluripotent stem cells (iPSCs), adult cells genetically reprogrammed to behave like embryonic ones, sidestep the embryo controversy entirely. Established uses include bone marrow transplantation for leukaemia, lymphoma and thalassemia, limbal stem cell grafts for corneal repair, and cartilage treatment; frontier research targets Parkinson's disease, spinal cord injury, diabetes through insulin-producing cells, and even lab-grown organs.

Transplant type

Stem cell source

Key risk

Autologous

The patient's own stem cells, collected from bone marrow or blood before treatment and re-infused after

Lower rejection risk, but diseased cells may be reintroduced

Allogeneic

Stem cells from a matched donor's bone marrow or blood

Graft-versus-host disease, in which donor cells attack the patient's tissues

Graft-versus-host disease (GVHD) is a condition in which transplanted donor stem cells recognise the patient's body as foreign and attack it, causing skin rash, diarrhoea and liver damage. Transplant conditioning also wipes out the patient's immune system, inviting infection, and the procedures can cause infertility, nausea and fatigue. The regulatory line hardened in September 2026, when the Union health ministry directed states to act against clinics selling unproven stem cell therapies, for autism or anti-ageing for instance: stem cell therapy may now be offered only for listed conditions, 18 in adults and 14 in children, and the National Medical Commission has warned that prescribing it beyond approved indications counts as professional misconduct.

India regulates the field through the National Guidelines for Stem Cell Research (ICMR-DBT, 2017), which set the ethical and scientific framework, and under the New Drugs and Clinical Trials Rules of 2019, stem cell products are legally classified as drugs. The ICMR Stem Cell Registry tracks clinical trials, DBT supports facilities such as the National Centre for Cell Science in Pune, and Stempeucel, developed indigenously, became the first Indian stem cell product to win limited manufacturing approval from the CDSCO for critical limb ischemia. The caution UPSC expects: unproven stem cell clinics selling miracle cures remain a regulatory challenge, which is why the guidelines draw a sharp line between approved trials and commercial exploitation.

Health goes digital

Digital health is the use of digital technologies, telemedicine, electronic records, diagnostics software and data platforms, to make healthcare more accessible, efficient and personalised. In a country where specialists cluster in cities and patients crowd distant hospitals, the screen has become a stethoscope's extension.

The flagship is the Ayushman Bharat Digital Mission (ABDM), which builds a national digital health ecosystem on layered registries. Its foundation is ABHA, the Ayushman Bharat Health Account, a 14-digit health ID that gives every citizen a longitudinal health record across providers; over over 84 crore ABHA IDs had been generated by the end of 2025, crossing 90 crore in 2026. Above it sit the Healthcare Professionals Registry and the Health Facility Registry, and the Unified Health Interface (UHI) is the protocol meant to let any health app talk to any doctor or lab. On this rails run e-Sanjeevani, the free telemedicine platform that has served nearly 50 crore consultations as of September 2026, the e-Hospital system digitising over a thousand government hospitals, and the Integrated Health Information Platform (IHIP), which tracks 33 notifiable diseases in real time for outbreak response.

The fault lines are equally examinable. An alleged leak of over 10 lakh CoWIN user records in 2023 exposed data-security gaps. The digital divide persists, with rural internet penetration far below urban levels, which limits who can actually use these platforms. Many state systems still do not talk to private hospitals, ASHA workers struggle with data-entry apps, and algorithmic bias is a live concern as AI diagnostic tools trained on foreign data get deployed on Indian patients. The 2020 telemedicine guidelines were a start, but liability for AI-assisted diagnosis and prescription fraud remain under-regulated, the classic mains tension between innovation and safeguards.

Ancient wisdom, modern proof: traditional medicine

The World Health Organization defines traditional medicine as the knowledge, skills and practices based on the theories, beliefs and experiences indigenous to different cultures, used to maintain health and to prevent, diagnose or treat illness. In India this is not folklore on the margins: it is a recognised AYUSH system, an acronym for Ayurveda, Yoga and Naturopathy, Unani, Siddha, Homeopathy and Sowa-Rigpa, the Tibetan system added in 2010, administered by a dedicated Ministry of AYUSH created in 2014.

The institutional push has been substantial. The National Ayush Mission has operationalised 12,260 Ayushman Arogya Mandirs (Ayush) as of September 2026, against a target of 12,500, bringing traditional care into primary health infrastructure. In 2022 India hosted the WHO Global Centre for Traditional Medicine at Jamnagar, Gujarat, the first institution of its kind in the world, backed by a Rs 2,000 crore commitment, to build evidence, data and standards for traditional systems globally. Ayush-64, a polyherbal formulation clinically studied during COVID-19, became the emblem of evidence-based promotion, and an AYUSH Export Promotion Council now chases a multi-billion-dollar global wellness market, with Kerala and Uttarakhand drawing medical tourists for Ayurvedic therapies.

The scepticism is substantive and UPSC-grade. WHO itself notes the thin global evidence base for many traditional claims; reports of heavy-metal contamination in some Ayurvedic formulations have hurt credibility abroad; the Pharmacopoeia Commission for Indian Medicine and Homoeopathy is still building quality standards; the Drugs and Cosmetics Act of 1940 lacks uniform clinical-trial norms for herbal drugs; and the policy consensus emerging is integration with validation: mainstream AYUSH in primary and preventive care, especially where allopathy is thin, but only with the same pharmacovigilance and trials that modern drugs face.

When medicines fail: drug quality and regulation

India's title as pharmacy of the world rests on trust, and trust has been shaken. Deaths of children from diethylene glycol-contaminated cough syrups, in Gambia and Uzbekistan in 2022 and in Indian states in 2025, including the Coldrif cough-syrup tragedy in Chhindwara, Madhya Pradesh, where the syrup tested at 48.6 percent DEG and killed 24 children, exposed how weak domestic drug regulation can turn deadly. Understanding the regulatory architecture is therefore as much a governance topic as a science one.

The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India, is the national regulator for new drugs, clinical trials and imports, while State Drug Regulatory Authorities license manufacturing and sale within states. The governing law is the Drugs and Cosmetics Act of 1940, a pre-independence statute critics call outdated for biologics and complex global supply chains. The Act classifies failures precisely: not of standard quality (NSQ) drugs miss specifications; spurious drugs carry fake labels; misbranded drugs mislead; adulterated drugs contain toxic or filthy substances.

Reform is underway but incomplete. Schedule M of the rules was revised to align with WHO good manufacturing practices, special courts were created for drug offences, a scheme to strengthen state regulatory systems is upgrading laboratories, and the CDSCO now publishes monthly lists of NSQ drugs. The deeper fix experts demand is structural: replace the 1940 Act with a modern law covering biologics and medical devices, build a unified and genuinely empowered national regulator, staff and equip state authorities, and make approvals, inspections and recalls fully transparent. Quality, the argument runs, is what converts manufacturing scale into lasting soft power.

Price control has its own separate architecture, and it is worth learning as a box of its own. The Drugs (Prices Control) Order, 2013 — the DPCO — is issued under the Essential Commodities Act, 1955, which empowers the Centre to regulate the prices of essential goods, and it is the primary framework governing medicine prices in India. The National Pharmaceutical Pricing Authority, set up in 1997 under the Department of Pharmaceuticals, implements the order.

The DPCO divides medicines into scheduled and non-scheduled formulations, a formulation being a medicine in a particular strength and dosage form. Scheduled formulations are those listed in Schedule I of the order, which is drawn from the National List of Essential Medicines — the NLEM, prepared by the Ministry of Health and Family Welfare — and their prices are capped at a ceiling price. Non-scheduled formulations sit outside that list: the pricing authority monitors their prices and can step in with corrective measures, including price regulation, when they rise unreasonably.

Mission / plan

What it does

Key instrument

National TB Elimination Programme

Find, treat and support every TB patient

Nikshay Poshan Yojana nutrition transfers

Ayushman Bharat Digital Mission

National digital health ecosystem

ABHA 14-digit health ID

Universal Immunisation Programme

Free vaccines against 12 diseases since 1985

Co-WIN tracking

National Ayush Mission

Mainstream traditional systems in public health

12,260 Ayushman Arogya Mandirs (Ayush)

National Action Plan on AMR 2.0

Contain drug resistance via One Health

Red Line campaign, surveillance network

The world's first pandemic treaty

The WHO Pandemic Agreement is the first global treaty on pandemic preparedness, prevention and response, adopted on 20 May 2025 at the 78th World Health Assembly under Article 19 of the WHO Constitution. It is only the second legally binding instrument the WHO has ever adopted under that article, after the Framework Convention on Tobacco Control of 2003.

Negotiations began in December 2021, during the Omicron wave of Covid-19, driven by the memory of vaccine nationalism: wealthy countries locking up early vaccine supplies while developing countries waited, and supply-chain breakdowns that left health systems exposed. Later studies estimated that more equitable vaccine distribution could have saved over a million additional lives.

The agreement seeks to strengthen international cooperation on surveillance, research and equitable access to vaccines, diagnostics and treatments, so the next pandemic does not repeat the access divides of Covid-19. For India, which positioned itself as a supplier of affordable vaccines and medicines, the treaty is both a responsibility and a strategic opening.

Beyond infections: India's NCD transition

Non-communicable diseases (NCDs) are medical conditions not caused by infectious agents, usually of long duration and slow progression. The big four are cardiovascular disease, diabetes, cancer and chronic respiratory illness. They now account for roughly 63 to 65 per cent of all deaths in India, up from about 38 per cent in 1990, a transition driven by urbanisation, ageing populations and changing diets.

The sting is in the age profile: about a quarter of NCD deaths in India occur between ages 30 and 70, striking people in their prime productive years. That makes NCDs not just a health issue but an economic one, eroding household incomes and workforce productivity decades before retirement age.

One dietary change sits behind much of the NCD story: added sugars. These are sweetening agents — syrups, sucrose, dextrose and the like — added to foods and beverages during processing, as distinct from the sugars that occur naturally in fruit or milk. They supply about 4 kilocalories per gram, the same as naturally occurring sugars, so their harm is not extra calories per gram but the calories they add without the nutrients of whole foods. The World Health Organization advises against introducing added sugars before the age of two years, and diets heavy in them are linked to obesity and diabetes — the two conditions driving the NCD transition described above.

The global net against superbugs

India does not fight AMR alone. GLASS, the Global Antimicrobial Resistance and Use Surveillance System launched by WHO in 2015, standardises how countries track resistant infections, so outbreaks can be compared across borders and spotted early.

GARDP, the Global Antibiotic Research and Development Partnership backed by WHO, funds new antibiotics for drug-resistant infections that commercial markets ignore. Its SECURE programme works to expand access to essential antibiotics in low- and middle-income countries, while Carb-X, another global nonprofit partnership, accelerates early-stage antibacterial innovation.

The way forward, as global agencies frame it: update the 2015 Global Action Plan on AMR through the Quadripartite of FAO, UNEP, WHO and the World Organisation for Animal Health; write defined antibiotic-use policies for hospitals; promote alternatives to antibiotics; expand financing instruments; and run the whole effort as One Health, linking human, animal and environmental health.

TB's final push: new weapons

The regimen revolution has arrived. India has moved to the BPaL/BPaLM all-oral regimen for drug-resistant TB, phasing out painful daily injections: the six-month BPaLM course is markedly more effective than older treatments, and oral bedaquiline-based regimens have pushed DR-TB treatment success from 68 per cent in 2020 to 75 per cent by 2022. Newer drugs bedaquiline and delamanid are now rolled out for safer, more effective drug-resistant TB care.

The regimen’s full name is worth spelling out: BPaL combines three drugs — bedaquiline, pretomanid and linezolid — into a six-month, all-oral course that the World Health Organization recommends for eligible patients with drug-resistant TB. The related BPaLM regimen has recorded a treatment success rate of about 89 per cent, against 52 to 75 per cent for the standard regimens it replaces, and more than 15,000 patients had already started BPaLM treatment under the national programme.

Vaccines may be next. India is in advanced Phase III trials for two TB vaccines: VPM1002, a recombinant BCG vaccine, and MIP (Mycobacterium indicus pranii), an Indian-developed candidate.

The numbers show the push is working: TB incidence fell 17.7 per cent between 2015 and 2023, double the global average decline of 8.3 per cent, while treatment coverage rose from about 53 per cent in 2015 to 85-89 per cent by 2023. New instruments include the Ni-kshay 2.0 portal for unified patient management and benefit tracking, and the TB Mukt Panchayat initiative, which awards TB-free status to gram panchayats to build local accountability.

Trachoma and the neglected diseases

Trachoma is a bacterial eye infection caused by Chlamydia trachomatis, spread through eye secretions, fingers, clothes and flies, and classified by WHO as a neglected tropical disease; untreated, it blurs vision and can cause blindness. WHO declares trachoma eliminated as a public health problem when trichiasis prevalence falls below 0.2 per cent in people over 15 and active trachoma below 5 per cent in children aged 1-9. India met these criteria and became the third country in South-East Asia, after Nepal and Myanmar, to eliminate trachoma.

Trachoma sits inside a bigger map. Neglected tropical diseases (NTDs) are a group of 21 conditions prevalent in tropical and subtropical regions, affecting over a billion people in impoverished communities, and caused by viruses, bacteria, protozoa and parasitic worms. They are called neglected because they are nearly absent from the global health agenda, receiving less than 0.6 per cent of global health funding despite their burden, and India carries the world's largest absolute burden of at least 10 major NTDs. The WHO NTD Roadmap 2021-2030 charts elimination targets; progress needs funding, surveillance, and honest attention to stigma, climate-driven spread and drug resistance.

Nobel 2025: the immune system's peacekeepers

The 2025 Nobel Prize in Physiology or Medicine went to Mary Brunkow and Fred Ramsdell (USA) and Shimon Sakaguchi (Japan) for discoveries on peripheral immune tolerance. Sakaguchi discovered regulatory T cells (Tregs) in 1995; Brunkow and Ramsdell showed in 2001 that mutations in the FOXP3 gene cause the rare autoimmune disease IPEX; Sakaguchi then linked the two, showing FOXP3 controls Treg development.

A regulatory T cell is a specialised T cell that stops the immune system from attacking the body's own tissues. Peripheral tolerance is the system of checks in body tissues that keeps leftover self-reactive cells from activating, and Tregs are its central enforcers. Their failure underlies autoimmune disorders such as rheumatoid arthritis, type 1 diabetes and multiple sclerosis, which is why the discovery opens new therapeutic doors.

Three-parent babies: mitochondrial donation

Mitochondrial donation treatment (MDT), also called mitochondrial replacement therapy (MRT) or the 'three-parent baby' technique, is a specialised in-vitro fertilisation (IVF) technique designed to prevent the transmission of mitochondrial diseases from mother to child. It uses the nuclear genetic material of the parents and the healthy mitochondrial material of a donor: the baby carries almost all its DNA from its parents and a small fraction, about 37 genes, from the donor.

Mitochondrial replacement: three parents, one embryoParentsmother: faulty mitochondriafather: spermnuclear DNA from bothDonor egghealthy mitochondriadonor nucleus removedonly cytoplasm is usedThree-parent embryonuclear DNA: the parentsmitochondria: the donormitochondrial disease avoided
Mitochondrial replacement therapy: the nuclear DNA of the parents is combined with healthy mitochondria from a donor egg, so the child inherits the parents' genes without the mother's faulty mitochondrial DNA.

In May 2023 the UK's Human Fertilisation and Embryology Authority confirmed the first British babies born through MDT, fewer than five at the time, with more than 99.8 percent of their DNA from the parents. Britain had become the first country to legalise the technique in 2015, using maternal spindle transfer or pronuclear transfer at the Newcastle Fertility Centre; the first such birth anywhere was in Mexico in 2016.

In India the procedure is not currently permitted, and ethicists argue that any introduction would need a dedicated regulatory body, proper clinical trials and safeguards against the exploitation of egg donors, alongside answers on the child's identity rights, equitable access and the technique's still-experimental safety record.

Diseases: pathogen, carrier and cure

The disease table the paper returns to every year, grouped by the kind of organism that causes each disease.

  • Protozoan diseases: malaria, caused by Plasmodium and spread by the female Anopheles mosquito; kala-azar, spread by the sandfly; amoebic dysentery, spread by contaminated food and water; sleeping sickness, spread by the tsetse fly.
  • Viral diseases: polio, smallpox (eradicated in 1980), chickenpox, hepatitis A, B, C, D and E, AIDS (HIV), dengue and chikungunya (both spread by the Aedes mosquito), rabies (dog bite), measles and influenza. Hepatitis A and E spread through contaminated food and water, hepatitis B, C and D spread through blood and body fluids, and D occurs only together with B.
  • Bacterial diseases: cholera, typhoid, tuberculosis, tetanus, leprosy, diphtheria, plague, pneumonia, syphilis and gonorrhoea. Syphilis is caused by Treponema pallidum and gonorrhoea by Neisseria gonorrhoeae, and both spread by sexual contact.
  • Helminth diseases: tapeworm, hookworm and elephantiasis or filariasis, spread by mosquitoes.
  • Fungal diseases: ringworm and athlete's foot.
  • Environment-linked diseases: Minamata disease from mercury poisoning, Itai-itai from cadmium, blue-baby syndrome from excess nitrate in water and black-foot disease from arsenic.
  • Blue-baby disease: methaemoglobinemia, caused by excess nitrate in drinking water. Nitrate converts haemoglobin into methaemoglobin, which cannot carry oxygen, so the baby's skin turns blue.
  • Black-foot disease: arsenic poisoning from drinking arsenic-contaminated groundwater. It darkens and hardens the skin of the feet and can end in gangrene.

Asked in SSC CGL 2026

Vaccines, antibiotics and medical tests

  • BCG: the vaccine against tuberculosis, developed by Calmette and Guerin.
  • DPT: protects against diphtheria, pertussis (whooping cough) and tetanus.
  • Polio vaccines: Salk's injectable vaccine and Sabin's oral vaccine.
  • Penicillin: the first antibiotic, discovered by Alexander Fleming from the mould Penicillium.
  • Insulin: isolated by Banting and Best for the treatment of diabetes.
  • Rh factor: discovered by Karl Landsteiner, who also discovered the ABO blood groups.
  • Genetic code: worked out by Har Gobind Khorana. DNA itself was first isolated by Friedrich Miescher, and its double-helix structure was described by Watson and Crick in 1953.
  • Virus and vitamins: the virus was discovered by Ivanovsky, and the word vitamin was coined by Casimir Funk. The rabies vaccine was developed by Louis Pasteur.
  • Medical tests: CT gives cross-sectional images of the body, ECG records the electrical activity of the heart, EEG records the electrical activity of the brain, MRI uses magnetic fields to image soft tissue, X-ray images bones, ultrasound uses sound waves, dialysis cleans the blood when the kidneys fail, and angioplasty opens narrowed blood vessels.
  • Vaccines and immunity: a vaccine trains the immune system to recognise a germ. The antibody titre is the measure of antibodies in the blood, and it shows how strong the immune response is.
  • Discoverers of the cell: Walther Flemming described chromosomes and mitosis. Carl Benda coined the term mitochondria in 1898. Camillo Golgi described the Golgi body in 1898. George Palade discovered the ribosome in 1955.
  • Malaria and kala-azar: Ronald Ross proved in 1897 that the Anopheles mosquito carries the malaria parasite, and won the Nobel Prize in 1902. Upendranath Brahmachari discovered urea stibamine, the first effective treatment for kala-azar, in 1922.

Asked in SSC CGL 2026

Frequently asked questions

What is the Red Line campaign?

It is an awareness initiative that requires antibiotic strips to carry a red vertical stripe, signalling that the medicine should be taken only on a doctor's prescription. It is one of the most visible tools in India's fight against self-medication-driven antimicrobial resistance.

How is ZyCoV-D different from other COVID vaccines?

ZyCoV-D is the world's first plasmid DNA vaccine approved for human use. Instead of delivering a weakened virus or mRNA, it delivers a DNA plasmid carrying the spike-protein gene, and it is administered needle-free with a jet injector. It was granted emergency authorisation in August 2021 for ages 12 and above.

What does ABHA stand for and what does it do?

ABHA stands for Ayushman Bharat Health Account. It is a 14-digit health ID under the Ayushman Bharat Digital Mission that links a citizen's health records across hospitals, labs and apps into one longitudinal record, so medical history travels with the patient instead of staying locked in one hospital's files.

Why is tuberculosis hard to eliminate in India despite being curable?

Four reasons dominate: drug resistance (MDR and XDR strains need longer, costlier treatment), undernutrition as the biggest risk factor, delayed diagnosis with lakhs of unnotified cases in the private sector, and social stigma that keeps patients from seeking care. The NTEP attacks all four together, which is why elimination is framed as a systems challenge, not just a medical one.

Vepdegestrant: the first PROTAC drug

On 1 May 2026 the United States Food and Drug Administration approved vepdegestrant, the first therapy based on PROTAC technology ever to reach patients. It is a first-in-class, once-daily oral targeted therapy for adults with advanced or metastatic breast cancer that is oestrogen receptor positive, HER2 negative and ESR1 mutated, after the disease has progressed on endocrine therapy. Co-developed by Arvinas and Pfizer, it is sold in the United States under the brand name Veppanu, at a dose of 200 mg once daily.

How a PROTAC works

  • Two-handed molecule: one end of the PROTAC binds the target protein, the other binds an E3 ubiquitin ligase.
  • Complex formation: the PROTAC brings the two together into a temporary complex.
  • Ubiquitination: the E3 ligase attaches ubiquitin molecules to the target protein, marking it for destruction.
  • Degradation: the cell's proteasome recognises the tagged protein and breaks it down.
  • Reuse: the PROTAC molecule survives the process and can tag further copies of the target protein.
PROTAC: tag the protein, do not just block itTarget proteinoestrogen receptor(in vepdegestrant)PROTAC moleculetwo-handed:binds both sidesE3 ligaseattaches ubiquitintags to the targetUbiquitin tag + proteasometagged protein is brokendown by the proteasomePROTAC is reusedone molecule can tag manycopies of the targetFirst FDA-approved PROTAC: vepdegestrant, 1 May 2026
How a PROTAC works: one end binds the target protein and the other binds an E3 ubiquitin ligase. The ligase tags the target with ubiquitin, the proteasome breaks the tagged protein down, and the PROTAC molecule is freed to tag another copy. Vepdegestrant uses this to destroy the oestrogen receptor in ESR1-mutated breast cancer.

Vepdegestrant directs this machinery at the oestrogen receptor, the protein that drives growth in many breast cancers. Mutations in the ESR1 gene can make the receptor resist hormone-based treatment, so blocking the receptor stops working. Destroying the receptor attacks the resistance itself. In the phase III VERITAC-2 trial, median progression-free survival in the ESR1-mutated group was 5.0 months with vepdegestrant against 2.1 months with fulvestrant. The contrast to memorise is simple: conventional drugs block a disease protein, a PROTAC removes it.

RK-251: a smart drug that switches on inside tumours

RK-251 is a novel smart cancer drug highlighted by the Ministry of Science and Technology in 2026 as a possible alternative to conventional chemotherapy. It was developed through a collaboration led by Dr Asis Bala of the Institute of Advanced Study in Science and Technology and Dr K. P. Bhabak of IIT Guwahati, under the Department of Science and Technology.

  • Trigger: cancer cells commonly carry higher levels of reactive oxygen species (ROS) than healthy cells. RK-251 stays inactive until it meets that high-ROS environment.
  • Payload: once activated, it releases NBDHEX, its anticancer component.
  • Target: NBDHEX acts on proteins that help cancer cells survive and develop resistance to treatment.
  • Selectivity: because the drug activates mainly inside cancer cells, healthy tissue is largely spared, unlike conventional chemotherapy, which damages dividing healthy cells as well.
RK-251: switched on by the tumour itselfNormal cell: low ROSRK-251 stays inactive,healthy tissue largelysparedCancer cell: high ROSdrug activates andreleases NBDHEXNBDHEX attacks survival proteinstargets proteins that help cancercells survive and resist treatmentContrast with chemotherapy, which damages dividing healthy cells too
RK-251 (IASST and IIT Guwahati, DST): in normal tissue, where reactive oxygen species are low, the drug stays inactive. In cancer cells, where ROS levels are higher, it activates and releases NBDHEX, which acts on proteins that help cancer cells survive and resist treatment.

The prelims fact is the mechanism, not the molecule: a drug that uses a chemical difference between a tumour cell and a normal cell as its own on-switch.

Intismeran: a cancer vaccine built from the patient's own tumour

Intismeran (also coded V940 or mRNA-4157) is a personalised mRNA-based cancer vaccine developed by Moderna and Merck that has shown promising results in melanoma, a type of skin cancer. It is personalised in the literal sense: no two doses are the same, because each dose is designed from the mutations in one patient's tumour.

How it is made and used

  • Step 1, read the tumour: the mutations present in the individual patient's tumour are analysed to identify tumour-specific proteins called neoantigens.
  • Step 2, encode 34 neoantigens: each treatment carries synthetic mRNA with instructions for cells to produce 34 of these neoantigens, which act as a unique fingerprint of that patient's cancer cells.
  • Step 3, train the immune system: after administration, the body produces the encoded neoantigens and presents them to the immune system, teaching it to recognise and attack cancer cells carrying those mutations.
  • Combination: intismeran is given together with Keytruda (pembrolizumab), an immunotherapy drug, to strengthen the immune response against the cancer.
Intismeran: a vaccine made for one patient1. Read the tumouranalyse mutations,find neoantigens2. Encode 34synthetic mRNA for34 neoantigens3. Train immunitycells make neoantigens,immune system learns4. Add Keytrudapembrolizumabstrengthens responseNeoantigens: the unique fingerprint of that patient's cancereach dose is different, because each tumour is differentContrast with a conventional vaccine, identical for every recipient
Intismeran (Moderna and Merck, also V940 or mRNA-4157): the patient's tumour mutations are analysed to identify neoantigens, synthetic mRNA encoding 34 of them teaches the immune system to recognise the cancer, and the vaccine is given with Keytruda (pembrolizumab) immunotherapy. Promising results in melanoma.

Contrast this with a conventional vaccine, which is identical for every recipient. A personalised cancer vaccine is manufactured for one patient, from that patient's own tumour, and its value lies in teaching the immune system to spot what makes that tumour different from healthy tissue.

Snakebite becomes a notifiable disease in Maharashtra

The Maharashtra government has declared snakebite a notifiable disease. A notifiable disease is one that health workers and institutions are legally required to report to government health authorities, so that the state can track it, spot outbreaks early, and respond before cases multiply.

  • Purpose: disease surveillance, early warning and outbreak control.
  • Who decides: state governments determine which diseases must be notified within their jurisdiction.
  • Criteria: public-health importance, severity and mortality, communicability, outbreak potential, risk of international spread, and relevance to national or international disease-control programmes.
  • Examples: cholera, tuberculosis, AIDS and dengue are notifiable diseases in India.
  • Legal framework: the Epidemic Diseases Act, 1897 provides the framework for disease notification in India.
  • Global framework: the World Health Organization's International Health Regulations provide the framework for international disease notification and global health surveillance.

Snakebite is a useful prelims example because it shows notification is not only about infections that spread person to person. A condition can be notified because it kills, because it clusters in particular seasons and occupations, and because counting cases is the first step to stocking antivenom where it is needed.

Resistant Gram-negative infections: costlier and deadlier

An Indian study has found that antibiotic-resistant Gram-negative infections among hospitalised patients are associated with higher mortality and higher treatment costs. It is one more data point in the antimicrobial resistance story this article opens with, and it names the organisms doctors worry about most in hospital wards.

  • Cell structure: Gram-negative bacteria have a thin peptidoglycan cell wall and an additional outer membrane containing lipopolysaccharides.
  • Gram staining: they appear pink or red under Gram staining, while Gram-positive bacteria appear purple. The outer membrane is part of why many antibiotics struggle to reach them.
  • Examples: Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
  • Why it matters: resistance in these organisms turns routine hospital care riskier and more expensive, because the drugs that still work are often costlier, more toxic, or needed for longer.

Read this alongside the antimicrobial resistance section: the same drivers, overuse in clinics, misuse in farms and weak enforcement, produce the resistant Gram-negative infections that now raise both death rates and hospital bills.

SCAD: the heart attack without plaque

World Heart Day, observed on 29 September 2026 under the theme Don't Miss a Beat, brought attention to a condition that contradicts the usual story of heart disease: spontaneous coronary artery dissection, or SCAD — a heart attack caused not by a blocked artery full of plaque, but by a tear in the artery wall itself.

In SCAD, the inner lining of a coronary artery tears, allowing blood to collect within the wall and form an intramural haematoma. The haematoma compresses the artery from inside, narrowing or blocking blood flow to the heart muscle. The mechanism matters because it overturns the default assumption: a SCAD patient can have no plaque, no cholesterol problem and none of the conventional risk factors — and still have a heart attack.

The profile is the exam's sharpest point. SCAD predominantly affects women in their forties and fifties, and it is the leading cause of heart attack in pregnancy and the postpartum period. Associated conditions include fibromuscular dysplasia, a disorder of artery walls, and triggers can include extreme physical or emotional stress. Because it strikes people who look low-risk, SCAD is the condition behind the campaign's warning not to dismiss chest pain in a young, apparently healthy woman.

The outcome can be as serious as any heart attack — arrhythmia, sudden cardiac death — but the treatment often differs. Where blood flow is adequate and the patient is stable, doctors frequently choose conservative management, letting the artery heal on its own rather than stenting a fragile, torn wall. That contrast — same emergency, different playbook — is why SCAD belongs in the non-communicable-disease transition this article traces.

SCAD: the heart attack without plaqueHealthy arteryopen lumen; blood flowsfreely to the heart muscleSCAD arterytear lets blood collect in the wall;the haematoma squeezes the lumen shutMainly women in their 40s and 50sleading cause of heart attack in pregnancy and after birthSame emergency, different playbook: often conservative care, letting the artery heal on its own.
SCAD is a heart attack without plaque: the inner lining of a coronary artery tears, blood collects within the wall as a haematoma, and the haematoma compresses the artery from inside, narrowing or blocking blood flow to the heart muscle. It mainly affects women in their forties and fifties and is the leading cause of heart attack in pregnancy and the postpartum period; where flow is adequate and the patient is stable, doctors often choose conservative management and let the artery heal on its own.

Feature

Typical heart attack

SCAD

Cause

Plaque rupture and clot

Tear in the artery wall; blood collects within the wall

Plaque

Central to the disease

Usually absent

Who it strikes

Older adults with risk factors

Mainly women in their 40s–50s; pregnancy and postpartum

Treatment

Stent or bypass usually

Often conservative — the artery heals on its own if flow is adequate

Key Terms

  • One Health: One Health is the integrated approach that treats human, animal, and environmental health as interlinked, since most emerging infections are zoonotic. India has institutionalised it through the National One Health Mission, steered by the Principal Scientific Adviser with ICMR as implementing agency. For UPSC, it is the standard framework for answers on pandemic preparedness, antimicrobial resistance, and climate-linked disease. Example: Joint surveillance of avian influenza across poultry farms and nearby clinics is a textbook One Health intervention.
  • COVAXIN: COVAXIN is India's first indigenously developed COVID-19 vaccine, created by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology. It is a whole-virion inactivated vaccine, meaning it uses a killed SARS-CoV-2 virus to trigger immunity without causing disease, and it can be stored at ordinary refrigerator temperatures of 2 to 8 degrees Celsius. It received WHO emergency use listing in November 2021 and was a backbone of India's vaccination drive. Example: COVAXIN was exported to countries like Paraguay and Botswana during the pandemic under India's Vaccine Maitri initiative.
  • ABHA: The Ayushman Bharat Health Account is a 14-digit unique health identifier issued under the Ayushman Bharat Digital Mission. It lets an individual link prescriptions, lab reports and discharge summaries across hospitals and clinics, so records travel with the patient and can be shared with providers through consent-based digital exchange. For UPSC it is the identity layer of India's digital health stack and a standard example of technology-enabled, portable healthcare. Example: a patient's prescriptions and lab reports accessible to any empanelled hospital through consent-based sharing
  • AYUSH: AYUSH stands for Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy, India's recognised traditional systems of medicine. A dedicated Ministry of AYUSH was created in 2014 to regulate education, standardise practice and fund research, while the National AYUSH Mission mainstreams these systems into public healthcare alongside allopathy. UPSC examines AYUSH in health policy, integrative medicine, clinical-trial standards and India's wellness and traditional-medicine diplomacy. Example: the National AYUSH Mission co-locating AYUSH facilities in primary health centres
  • Drugs and Cosmetics Act of 1940: The Drugs and Cosmetics Act, 1940 is India's principal law regulating the import, manufacture, distribution and sale of drugs and cosmetics to ensure quality and safety. It prescribes statutory quality standards (through its Schedules), a licensing system for manufacturers and sellers, and penalties including imprisonment for offences such as manufacturing spurious, adulterated or misbranded drugs. It is implemented by the CDSCO at the Centre and state drug control authorities. Example: Selling a substandard antibiotic without a proper manufacturing licence draws prosecution under this Act.
  • Antimicrobial resistance (AMR): Antimicrobial resistance is the ability of bacteria, viruses, fungi, and parasites to survive medicines designed to kill them, making common infections harder and costlier to treat. It is accelerated by overuse and misuse of antibiotics in human medicine and livestock, poor infection control, and weak regulation of drug sales. The WHO ranks AMR among the top global health threats, and India faces a particularly high burden. Example: Extensively drug-resistant tuberculosis (XDR-TB) in India and the spread of the NDM-1 resistance gene illustrate why AMR is a national health security issue.
  • National Action Plan on AMR 2.0 (2025-29): The National Action Plan on Antimicrobial Resistance 2.0 is India's updated five-year strategy (2025 to 2029) to combat antimicrobial resistance, launched by Union Health Minister J.P. Nadda in November 2025. It follows the first plan of 2017 and is built on the One Health approach, linking human health, animal health, food and the environment. It addresses gaps in the earlier plan by strengthening inter-sectoral coordination, laboratory surveillance, infection control and engagement with the private sector. Example: Kerala and Gujarat became the first states to ban over-the-counter sale of antibiotics, a step highlighted at the plan's launch.
  • Universal Immunisation Programme: The Universal Immunisation Programme is India's national vaccination programme, launched in 1985, providing free vaccines against 12 vaccine-preventable diseases including tuberculosis, polio, measles, hepatitis B and rotavirus diarrhoea. It covers about 2.7 crore newborns and 3 crore pregnant women each year, making it one of the world's largest public health programmes. For UPSC, it anchors health and social justice questions. Example: Mission Indradhanush, launched in 2014 under UIP, targets unvaccinated and partially vaccinated children.
  • Tuberculosis (TB): Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis, most commonly attacking the lungs and spreading through airborne droplets from coughing or sneezing. India carries the world's largest TB burden, and its National TB Elimination Programme targets ending TB by 2025, five years ahead of the global SDG deadline, using the Ni-kshay digital platform for patient tracking. Drug-resistant TB remains a major treatment challenge. Example: The BCG vaccine administered at birth, which protects young children against severe forms of TB.
  • National TB Elimination Programme (NTEP): The National TB Elimination Programme is India's flagship programme against tuberculosis, previously known as the Revised National Tuberculosis Control Programme until its renaming in 2020. It provides free diagnosis and treatment, including the Nikshay digital platform for patient tracking and Nikshay Poshan Yojana, which gives direct benefit transfers to TB patients for nutrition. India has set the ambitious target of ending TB by 2025, five years ahead of the global SDG target of 2030. Example: A TB patient registered on Nikshay receives Rs 1,000 per month under Nikshay Poshan Yojana for nutritional support during treatment.
  • Multidrug-resistant TB (MDR-TB): Multidrug-resistant tuberculosis is a form of TB caused by strains of Mycobacterium tuberculosis that do not respond to at least isoniazid and rifampicin, the two most powerful first-line anti-TB drugs. It arises mainly when patients receive inadequate, interrupted, or incorrect treatment, and it requires longer, costlier second-line regimens with more side effects. India carries one of the world's largest MDR-TB burdens, and rapid molecular tests such as CBNAAT are used for early detection. Example: India's National TB Elimination Programme provides free second-line drug regimens for drug-resistant TB under its programmatic management component.
  • Induced pluripotent stem cells (iPSCs): Induced pluripotent stem cells are adult cells, such as skin cells, that scientists have reprogrammed back into an embryo-like state in which they can develop into almost any cell type in the body. They are created by introducing a small set of genes, called Yamanaka factors, into ordinary cells. Because iPSCs come from the patient, they avoid both the ethical issues of embryonic stem cells and the risk of immune rejection. Example: iPSCs are used to grow patient-specific heart or nerve cells in the laboratory for disease modelling and drug testing.
  • Ayushman Bharat Digital Mission: The Ayushman Bharat Digital Mission, launched in September 2021, builds the digital backbone of India's health system on open, interoperable standards. Its building blocks include the Ayushman Bharat Health Account number for citizens, the Healthcare Professionals Registry and the Health Facility Registry, enabling consent-based sharing of digital health records across providers. It is a flagship UPSC example of digital public infrastructure applied to health. Example: Patients use their 14-digit ABHA number to link health records across different hospitals.
  • Central Drugs Standard Control Organisation (CDSCO): The Central Drugs Standard Control Organisation (CDSCO) is India's national drug regulator, functioning under the Directorate General of Health Services in the Ministry of Health and Family Welfare. Headed by the Drugs Controller General of India (DCGI), it approves new drugs and clinical trials, regulates drug imports, and lays down standards for drugs, cosmetics and medical devices under the Drugs and Cosmetics Act, 1940. State drug controllers handle manufacturing licences while CDSCO handles central approvals. Example: CDSCO granted emergency use authorisation to COVAXIN and Covishield during the COVID-19 pandemic in January 2021.
  • Mrna vaccine: An mRNA vaccine is a biological preparation that introduces a piece of messenger RNA corresponding to a viral protein, so the body's own cells manufacture the protein and the immune system learns to attack it. The mRNA does not enter the nucleus and does not alter the recipient's DNA.

Prelims practice

0 of 5 answered · 0 correct

Q1Prelims practice

With reference to antimicrobial resistance (AMR) in India, consider the following statements:

1. The Red Line campaign marks antibiotic strips with a red stripe to discourage self-medication.

2. The use of colistin as a growth promoter in poultry feed has been banned in India.

3. The National Action Plan on AMR 2.0 covers the period 2025-29.

Q2Prelims practice

ZyCoV-D, developed by Zydus Cadila, is notable because it is:

Q3Prelims practice

With reference to CERVAVAC, consider the following statements:

1. It is India's first indigenously developed quadrivalent HPV vaccine.

2. It was developed by the Serum Institute of India in partnership with DBT and BIRAC.

3. It protects against cervical cancer.

Q4Prelims practice

The ABHA ID under the Ayushman Bharat Digital Mission is:

Q5Prelims practice

With reference to tuberculosis control in India, consider the following statements:

1. Nikshay Poshan Yojana provides direct benefit transfers for nutritional support to TB patients.

2. India has moved drug-resistant TB treatment to an all-oral BPaLM regimen.

3. Ni-kshay Mitra allows citizens to adopt TB patients for nutritional support.

Mains Practice question

150 words: Antimicrobial resistance is a One Health challenge. Discuss the drivers of AMR in India and the policy response.

  • Define: AMR as microbes evolving past medicines; the silent pandemic framing.
  • Drivers: clinical overuse and Schedule H1 gaps; colistin in poultry and aquaculture; pharma effluents (Musi river); 156 irrational FDCs banned 2024; sanitation failures.
  • Response: NAP-AMR 2.0 (2025-29), Delhi Declaration 2017, Red Line campaign, ICMR surveillance network, India AMR Innovation Hub; Kerala and Gujarat OTC bans.
  • Way forward: diagnostics-led prescribing, clean pharma supply chains, farm traceability, behaviour change; One Health data-sharing across sectors.

250 words: India is the pharmacy of the world, yet its domestic drug regulation faces a credibility crisis. Critically examine.

  • The paradox: 3rd largest pharma producer by volume, 60 percent of global vaccine doses, yet DEG cough-syrup deaths (Gambia, Uzbekistan 2022; Indian states 2025).
  • Regulatory architecture: CDSCO and DCGI at Centre, state authorities for manufacturing, Drugs and Cosmetics Act 1940 as governing law.
  • Failures: outdated law, fragmented Centre-state jurisdiction, weak state labs and inspector shortages, opaque approvals, low conviction rates, poor pharmacovigilance.
  • Reforms: Schedule M aligned to WHO-GMP, special courts, state strengthening scheme, NSQ publication; demand: new law, empowered unified regulator, transparency.

150 words: Digital health can democratise healthcare in India, but the digital divide may deepen inequity. Discuss.

  • Promise: ABDM and ABHA IDs, e-Sanjeevani's 20 crore consultations, IHIP disease surveillance, e-Hospital efficiency.
  • Divide: rural-urban internet gap, ASHA digital literacy, non-interoperable systems, CoWIN 2023 leak and data security.
  • Regulation gap: 2020 telemedicine guidelines silent on AI liability and prescription fraud; algorithmic bias from foreign-trained models.
  • Balance: digital public infrastructure plus offline fallbacks, privacy law enforcement, capacity building for frontline workers.

India's First Government Hospital-Based AI Clinic

India's first government hospital-based Artificial Intelligence (AI) clinic was inaugurated at the Government Institute of Medical Sciences (GIMS), Greater Noida, Uttar Pradesh. The passage is a single line, and it gives no date, no description of what the clinic does and no detail of the AI tools involved — so this draft is deliberately short on specifics and long on why the idea matters. An AI clinic inside a government hospital is a different proposition from AI in a private chain: it brings diagnostic support, triage or record-keeping tools to patients who cannot pay for private care, and it tests whether such tools work in the crowded, resource-constrained conditions of a public hospital rather than in a controlled pilot. If it works there, it can be replicated across the public system; if it fails there, the failure teaches something a private-hospital trial never would. For prelims, the "first government hospital-based AI clinic" claim, the institute and its location are the recall facts; for mains, the clinic fits answers on AI in healthcare, on public health delivery, and on the challenge of taking a technology from demonstration to routine use in government hospitals.

Science TechHealth Technologyupsc-prelimsGS Paper 3explained

Asked in the mains

Previous-year questions from this topic

How UPSC has actually asked this topic — with the year and marks for each question.

  1. 201310 marks

    What do you understand by fixed dose drug combinations (FDCs)? Discuss their merits and demerits.

  2. 201412.5 marks

    Can overuse and the availability of antibiotics without doctor’s prescription, the contributors to the emergence of drug-resistant diseases in India? What are the available mechanisms for monitoring and control? Critically discuss the various issues involved.

  3. 201710 marks

    Stem cell therapy is gaining popularity in India to treat a wide variety of medical conditions including Leukaemia, Thalassemia, damaged cornea and several burns. Describe briefly what stem cell therapy is and what advantages it has over other treatments?

  4. 202015 marks

    COVID-19 pandemic has caused unprecedented devastation worldwide. However, technological advancements are being availed readily to win over the crisis. Give an account of how technology was sought to aid management of the pandemic.

  5. 202215 marks

    What is the basic principle behind vaccine development? How do vaccines work? What approaches were adopted by the Indian vaccine manufacturers to produce COVID-19 vaccines ?

Asked in the prelims

Previous-year MCQs from this topic

How UPSC has tested this topic in the prelims — pick an option to test yourself.

  1. 2020Prelims

    1.Consider the following statements: (1) Genetic changes can be introduced in the cells that produce eggs or sperms of a prospective parent. (2) A person’s genome can be edited before birth at the early embryonic stage. (3) Human induced pluripotent stem cells can be injected into the embryo of a pig. Which of the statements given above is/ are correct?

  2. 2019Prelims

    2.Which of the following are the reasons for the occurrence of multi-drug resistance in microbial pathogens in India? 1. Genetic predisposition of some people 2. Taking incorrect doses of antibiotics to cure diseases 3. Using antibiotics in livestock farming 4. Multiple chronic diseases in some people Select the correct answer using the code given below.

  3. 2012Prelims

    3.With reference to ‘stem cells’, frequently in the news, which of the following statements is/are correct? 1. Stem cells can be derived from mammals only. 2. Stem cells can be used for screening new drugs. 3. Stem cells can be used for medical therapies.

  4. 2010Prelims

    4.With regard to the transmission of the Human Immunodeficiency Virus, which one of the following statement if not correct?

  5. 2025Prelims

    5.With reference to monoclonal antibodies, consider the following: I. They are man-made proteins. II. They stimulate the patient’s immune system to fight the specific disease. III. They are produced using animal cells only. Which of the statements given above are correct?

  6. 2022Prelims

    6.In the context of vaccines manufactured to prevent COVID-19 pandemic, consider the following statements : 1. The Serum Institute of India produced COVID-19 vaccine named Covishield using mRNA platform. 2. Sputnik V vaccine is manufactured using vector based platform. 3. COVAXIN is an inactivated pathogen based vaccine. Which of the statements given above are correct?

  7. 2021Prelims

    7.With reference to recent developments regarding ‘Recombinant Vector Vaccine,’ consider the following statements: 1. Genetic engineering is applied in the development of these vaccines. 2. Bacteria and viruses are used as vectors. Which of the statements given above is/ are correct?

In current affairs

This topic in the news

Related articles

Continue your preparation with more on this topic.

Nuclear power in space: RTGs, reactors, propulsion and the law | UPSCScience & TechNuclear power in space: RTGs, reactors, propulsion and the lawBeyond Mars, sunlight is too weak for solar panels and a lunar night lasts two weeks. Nuclear power, from radioisotope generators to fission reactors and nuclear propulsion, is how deep-space missions and Moon bases will keep running, and the rules that must keep it safe.Defence technology for prelims: missiles, submarines, aircraft and DRDO | UPSCScience & TechDefence technology for prelims: missiles, submarines, aircraft and DRDOMissiles, submarines, fighter aircraft and the organisation that builds them: the defence technology facts prelims repeats, from Agni-V and BrahMos to Tejas, INS Arihant and INS Vagir, with tables and practice questions.Human biology facts for prelims: physiology, vitamins, diseases and cells | UPSCScience & TechHuman biology facts for prelims: physiology, vitamins, diseases and cellsPhysiology, vitamins and ICMR-NIN 2020 mineral intakes, diseases, cells and nutrition: the human biology facts prelims repeats, with tables, practice questions and model answers.Chemistry facts for prelims: periodic table, everyday chemicals, fuels and alloys | UPSCScience & TechChemistry facts for prelims: periodic table, everyday chemicals, fuels and alloysPeriodic table extremes, everyday chemicals with their common names, fuels, alloys, ores and polymers: the chemistry facts prelims tests, with tables, practice questions and model answers.General physics facts for prelims: SI units, mechanics, electricity, sound and light | UPSCScience & TechGeneral physics facts for prelims: SI units, mechanics, electricity, sound and lightSI units, scalar and vector quantities, mechanics worked values, electricity and magnetism, sound, light and heat: the general physics facts prelims repeats, with tables, practice questions and model answers.Nobel Prizes 2026: six laureates, six frontiers | UPSCScience & TechNobel Prizes 2026: six laureates, six frontiersOptogenetics, neutrino astronomy, asymmetric synthesis, Anne Carson, Navi Pillay and the microeconomics of stabilisation — all six 2026 Nobel Prizes in one note, with the laureates and citations to bank for prelims.